3B5 Stock Overview
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the Netherlands and rest of Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IGEA Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.001 |
| 52 Week High | CHF0.06 |
| 52 Week Low | CHF0.0005 |
| Beta | -1.31 |
| 1 Month Change | 0% |
| 3 Month Change | 100.00% |
| 1 Year Change | -90.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3B5 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -1.5% |
| 1Y | -90.9% | -9.0% | 0.9% |
Return vs Industry: 3B5 underperformed the German Medical Equipment industry which returned 9.4% over the past year.
Return vs Market: 3B5 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 3B5 volatility | |
|---|---|
| 3B5 Average Weekly Movement | 270.1% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3B5's share price has been volatile over the past 3 months.
Volatility Over Time: 3B5's weekly volatility has decreased from 361% to 270% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1 | Pierpaolo Cerani | www.igeapharma.nl |
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the Netherlands and rest of Europe. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; functional foods; and dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices.
IGEA Pharma N.V. Fundamentals Summary
| 3B5 fundamental statistics | |
|---|---|
| Market cap | €535.80k |
| Earnings (TTM) | -€11.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 3B5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3B5 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €11.56m |
| Earnings | -€11.56m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -47.1% |
How did 3B5 perform over the long term?
See historical performance and comparison